We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

38 hedge funds and large institutions have $11.5M invested in VYNE Therapeutics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 7

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

9% more funds holding

Funds holding: 35 → 38 (+3)

0.81% less ownership

Funds ownership: 47.9% → 47.09% (-0.81%)

51% less capital invested

Capital invested by funds: $23.4M → $11.5M (-$12M)

Holders
38
Holders Change
+3
Holders Change %
+8.57%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
15
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
DCM
DAFNA Capital Management
California
+$1.57M
2
ACA
Acorn Capital Advisors
New York
+$810K
3
PSC
Patient Square Capital
California
+$633K
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$468K
5
EAM
Exome Asset Management
New York
+$269K

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$4.67M
2
UOC
UBS O'Connor
Illinois
-$493K
3
Citadel Advisors
Citadel Advisors
Florida
-$320K
4
SSA
Schonfeld Strategic Advisors
New York
-$226K
5
Jane Street
Jane Street
New York
-$68K
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
1
Eventide Asset Management
Massachusetts
$2.37M – – –
Citadel Advisors
2
Citadel Advisors
Florida
$1.74M -$320K -130,128 -11%
ACA
3
Acorn Capital Advisors
New York
$1.24M +$810K +328,968 +72%
DCM
4
DAFNA Capital Management
California
$1.01M +$1.57M +636,103 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$752K +$1.28K +521 +0.1%
EAM
6
Exome Asset Management
New York
$731K +$269K +109,367 +31%
PAI
7
Palo Alto Investors
California
$704K – – –
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$544K +$468K +190,000 +123%
PSC
9
Patient Square Capital
California
$406K +$633K +257,033 New
PHP
10
Parkman Healthcare Partners
Connecticut
$344K +$160K +65,005 +42%
PCM
11
Prelude Capital Management
New York
$224K +$202K +82,102 +138%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$211K -$3.76K -1,527 -1%
Renaissance Technologies
13
Renaissance Technologies
New York
$182K +$222K +90,200 +362%
SSA
14
Schonfeld Strategic Advisors
New York
$134K -$226K -91,680 -52%
BlackRock
15
BlackRock
New York
$130K -$1.81K -735 -0.9%
ACM
16
ADAR1 Capital Management
Texas
$111K +$173K +70,419 New
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$91.3K -$32.2K -13,070 -18%
BCM
18
Bridgeway Capital Management
Texas
$82.1K +$36.9K +15,000 +41%
SCA
19
STALEY CAPITAL ADVISERS
Pennsylvania
$81.3K +$36.9K +15,000 +41%
UOC
20
UBS O'Connor
Illinois
$72K -$493K -200,243 -81%
XT
21
XTX Topco
Cayman Islands
$52.2K +$29.6K +12,034 +57%
HF
22
HRT Financial
New York
$41K +$64.6K +26,242 New
Northern Trust
23
Northern Trust
Illinois
$37.9K – – –
VF
24
Virtu Financial
New York
$31K +$48.2K +19,574 New
Commonwealth Equity Services
25
Commonwealth Equity Services
Massachusetts
$29K – – –
1
2

VYNE Hedge Fund Activity: Q1 2025 in Review

38 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2025, worth a combined $11.5M — down 51% from $23.4M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new VYNE positions and 4 closed out — a net gain of 3 holders — while 15 added to existing stakes and 7 trimmed.

The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $1.57M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $4.67M sold.

  • 38 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2025, up from 35 in Q4 2024.
  • Funds reported $11.5M of VYNE Therapeutics stock for Q1 2025, down 51% quarter-over-quarter.
  • 7 funds opened new VYNE Therapeutics positions in Q1 2025 and 4 closed out, a net change of +3 holders.
  • The largest VYNE Therapeutics buyer in Q1 2025 was DAFNA Capital Management, an estimated $1.57M added.
  • The largest VYNE Therapeutics seller in Q1 2025 was Cormorant Asset Management, an estimated $4.67M sold.

Based on aggregated 13F filings for Q1 2025.